Company / Capital Expenditures
ImmunityBio, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$3.8M
FY2025
5-year range
$3.8M / $78.2M
FY2021-FY2025
Trend
-44.2%
vs FY2024
Sector context
#82 of 194
Health Care
What the data says
At $4M, ImmunityBio, Inc.'s capital expenditures ranks #82 of 194 in the Health Care sector. Capital Expenditures has declined for 3 consecutive years, from $78M in FY2022 to $4M in FY2025.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of +18.2%.
Declined from $31M to $4M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -63.4%
- 5-Year CAGR
- +18.2%
- 10-Year CAGR
- -
Sector benchmark
#82 of 194 in Health CareTop 42% of 194This company $3.8M Sector average $117.5M
▼
-96.7% below sector average
Key checks
Key Insights
- ImmunityBio, Inc.'s capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of +18.2%, indicating consistent growth.
- In FY2025, capital expenditures decreased 44.2% year-over-year.
- Ranks #82 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.8M | -44.2% |
| FY2024 | $6.9M | -77.5% |
| FY2023 | $30.6M | -60.9% |
| FY2022 | $78.2M | +1723.2% |
| FY2021 | $4.3M | +156.9% |
| FY2020 | $1.7M | -61.1% |
| FY2019 | $4.3M | -34.6% |
| FY2018 | $6.6M | +192.7% |
| FY2017 | $2.2M | +853.6% |
| FY2016 | $235.0K | -89.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026